Repaglinide

• Description:

  Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

• Product Name Alternative:

  AG-EE 623ZW

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Repaglinide.html

• Concentration:

  10mM

• Purity:

  99.89

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  CC(C)C[C@H](NC(CC1=CC(OCC)=C(C(O)=O)C=C1)=O)C2=CC=CC=C2N3CCCCC3

• Molecular Formula:

  C27H36N2O4

• Molecular Weight:

  452.59

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore) . 2018 Sep;97 (38) :e12476.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  135062-02-1